Aptus Pharma IPO is an SME public issue opening for subscription from September 23 to September 25, 2025, with a price band of ₹65 to ₹70 per share. The company, headquartered in Ahmedabad, Gujarat, operates in the pharmaceutical marketing and distribution sector, focusing on finished formulations across various therapeutic areas. Aptus Pharma IPO offers investors exposure to a growing pharmaceutical distribution business with increasing revenues and an expanding footprint in the Indian healthcare market.
₹5
₹70
₹80.80
Expert Opinions
Market sentiment for Aptus Pharma IPO is cautiously positive as the company operates in the growing pharmaceutical distribution and marketing sector with improving financial metrics. The company’s strengths include a growing revenue base from ₹13.90 crore in FY 2023 to ₹24.64 crore in FY 2025 and enhancing profit margins supported by an operational model focused on finished drug formulations.
Risks include a leveraged balance sheet with borrowings exceeding net worth, working capital stress due to high inventory and receivables, and competition in the pharmaceutical distribution market. Valuation analysis of financial year 2025 for Aptus Pharma IPO shows a strong Return on Equity (ROE) of 44.50%, Return on Capital Employed (ROCE) of 45.66%, and a Net Asset Value (NAV) of ₹13.93, indicating efficient capital utilization. The IPO appeals to long-term investors seeking steady growth in the healthcare supply chain.
Investor Considerations
Aptus Pharma IPO has shown consistent revenue growth, increasing from ₹13.90 crore in FY 2023 to ₹24.64 crore in FY 2025, alongside improved profitability with PAT rising to ₹3.10 crore. The pharmaceutical distribution sector holds a positive outlook, driven by India’s growing healthcare demands and expanding therapeutic product range. The Aptus Pharma IPO valuation for FY 2025 reflects a strong Return on Net Worth (RoNW) of 44.50%, an EBITDA margin of 19.31%, and a Debt to Equity ratio of 1.49, indicating decent profitability but a leveraged balance sheet.
Growth prospects center on expanding distribution networks and broadening product offerings. Risk factors include working capital stress from high inventory and receivables, and competitive pressures. The IPO suits long-term investors seeking exposure to India’s evolving pharmaceutical market, while short-term investors should watch for liquidity and operational challenges.
| Date | GMP | Trend |
|---|---|---|
| 29 Sep 2025 13.16 | ₹5 | --- |
| 27 Sep 2025 17.10 | ₹5 | --- |
| 26 Sep 2025 12.41 | ₹5 | --- |
| 25 Sep 2025 16.56 | ₹5 | Down |
| 24 Sep 2025 12.16 | ₹10 | --- |
| 23 Sep 2025 10.33 | ₹10 | --- |
| 22 Sep 2025 12.03 | ₹10 | --- |
| 21 Sep 2025 19.18 | ₹10 | --- |
| 20 Sep 2025 13.28 | ₹10 | Up |
| 19 Sep 2025 11.16 | ₹00 | --- |
| 17 Sep 2025 15.26 | ₹00 | --- |
| 16 Sep 2025 20.27 | ₹00 | --- |
FAQs
The Grey Market Premium showed moderate accuracy in predicting Aptus Pharma IPO’s listing performance. With a final GMP of ₹5, it projected a premium of 7.14% over the issue price of ₹70. The stock listed at ₹80.80, delivering a gain of 15.43%. This resulted in a prediction error of 8.29%, where the GMP correctly signaled a positive listing but underestimated the actual gain, reflecting partial reliability in this case.
Aptus Pharma IPO Current GMP is ₹5.
Aptus Pharma IPO Expected Returns is 7.14%.
Aptus Pharma IPO estimated listing price is ₹75.